专注于计算预测和优化靶向蛋白质降解剂 (TPD) 的生物技术公司 Differentiated Therapeutics (dx/tx) 于8月1日宣布完成 500 万美元种子融资，本轮融资由Curie.Bio领投。

Distinguishing well-differentiated hepatocellular carcinoma (HCC) from benign hepatic lesions is challenging for pathologists in limited diagnostic material such as needle-core tissue biopsy and ...